The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early proliferation of PD-1+ CD8 T cells in peripheral blood as predictive of response to PD-1 inhibition for patients with advanced NSCLC.
 
Rathi Narayana Pillai
Consulting or Advisory Role - Natera
Travel, Accommodations, Expenses - Clovis Oncology; Genentech/Roche; Novartis; Takeda
 
Alice O. Kamphorst
No Relationships to Disclose
 
Shu Yang
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Eisai; G1 Therapeutics; Genentech/Roche; Lilly; Novartis; Sandoz; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
 
Gabriel Sica
No Relationships to Disclose
 
Tahseen Nasti
No Relationships to Disclose
 
Rama Akondy
No Relationships to Disclose
 
Andreas Wieland
No Relationships to Disclose
 
Hong Wu
No Relationships to Disclose
 
Nikita Patel
No Relationships to Disclose
 
Ke Yu
No Relationships to Disclose
 
Lydia Koenig
No Relationships to Disclose
 
Madhusmita Behera
No Relationships to Disclose
 
Megan McCausland
No Relationships to Disclose
 
Fadlo Raja Khuri
No Relationships to Disclose
 
Rafi Ahmed
Patents, Royalties, Other Intellectual Property - PATENT FOR THE TREATMENT OF PERSISTENT INFECTIONS AND CANCER BY INHIBITING THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY (Inst)
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer